Research on Lymphangioleiomyomatosis Disease Processes

Study of the Disease Process of Lymphangioleiomyomatosis

Recruiting Observational Study
Lung Disease Pneumothorax Tuberous Sclerosis Lymphangioleiomyomatosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
16 – 100
Sex
Any
Study type
Observational
Participants needed
2,000 (estimated)
Sponsor
National Heart, Lung, and Blood Institute (NHLBI) · NIH
Who this trial is looking for

This trial is looking for patients with a lung disease called lymphangioleiomyomatosis (LAM) and healthy volunteers to help understand how the disease affects the lungs. Taking part might involve medical tests and procedures to study the disease better.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with lymphangioleiomyomatosis.
  • I have findings on a lung biopsy that show LAM.
  • I have chest X-ray or CT scan results that show LAM.
  • I have tuberous sclerosis and also pulmonary LAM.
  • I am a normal non-smoker who has not smoked for at least a year.
  • I am a normal smoker who has smoked for at least a year and have normal lung tests.

You may not be able to join if

  • I am under 16 years old.
  • I have a serious other illness that makes the study too risky.
  • I am on continuous oxygen.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
* INCLUSION CRITERIA: General admission criteria for patients include one or both of the following: Findings on lung biopsy diagnostic of LAM; Findings on chest x-ray and/or chest computed axial tomography consistent with LAM. Patients with TSC and pulmonary LAM will be included in the study. N…
Contacts

Tatyana A Worthy, R.N.

(301) 827-1376

worthyt@mail.nih.gov

CONTACT

Joel Moss, M.D.

(301) 496-1597

mossj@nhlbi.nih.gov

CONTACT